A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Rheumatoid Arthritis.
Arthritis, Rheumatoid
About this trial
This is an interventional treatment trial for Arthritis, Rheumatoid focused on measuring Rheumatoid arthritis, infliximab, anti-TNF, methotrexate, safety and efficacy, Remicade
Eligibility Criteria
Inclusion Criteria: Patients must have a diagnosis of Rheumatoid Arthritis at least 3 months before screening If the patient is of childbearing potential, must have been using adequate birth control measures Patients must be receiving MTX for =3 months before randomization and at a stable dose(=25 mg/week) for =4 weeks before randomization Exclusion Criteria: Patients must not be pregnant, nursing, or planning a pregnancy within 18 months of enrollment Patients must not have rheumatic disease other than Rheumatoid Arthritis or had any systemic inflammatory condition Patients must not be confined to a wheelchair Patients must not be treated with any approved or investigational biologic agent except for approved vaccines for immunizations